Cargando…

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study

Detalles Bibliográficos
Autores principales:	Wang, Miao, Cao, Han-Yu, Tan, Kai-Wen, Qiu, Qiao-Cheng, Huang, Yuan-Hong, Ge, Shuai-shuai, Wang, Zi-Hao, Chen, Jia, Tang, Xiao-Wen, Wu, De-Pei, Xue, Sheng-Li, Li, Zheng, Dai, Hai-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682468/ https://www.ncbi.nlm.nih.gov/pubmed/38012154 http://dx.doi.org/10.1038/s41408-023-00948-x

Ejemplares similares

RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner
por: Abdallah, Mohamed Gaber, et al.
Publicado: (2021)

Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1–RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1–RUNX1T1
por: Cho, Byung-Sik, et al.
Publicado: (2021)

Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/RUNX1-RUNX1T1 Rearrangement
por: Tokunaga, Kenji, et al.
Publicado: (2017)

Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with RUNX1-RUNX1T1 Fusion
por: Yun, Jae Won, et al.
Publicado: (2019)

Volunteer unrelated donor cell‐derived acute myeloid leukemia with RUNX1‐RUNX1T1
por: Hagiwara, Shinya, et al.
Publicado: (2021)

Functional Characterization of Cooperating MGA Mutations in RUNX1::RUNX1T1 Acute Myeloid Leukemia
por: Klco, Jeffery, et al.
Publicado: (2023)

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
por: Mustafa Ali, Moaath K., et al.
Publicado: (2022)

Pseudo-Chediak-Higashi granules in myeloid cells in therapy-related AML with RUNX1-RUNX1T1
por: Cho, Sung Ran, et al.
Publicado: (2018)

Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1
por: Shaikh, Anam Fatima, et al.
Publicado: (2020)

Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with RUNX1::RUNX1T1
por: Hwang, Sang Mee, et al.
Publicado: (2022)

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
por: Hornung, Roman, et al.
Publicado: (2018)

Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 Fusions
por: Qin, Wei, et al.
Publicado: (2022)

Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report
por: Park, Suji, et al.
Publicado: (2023)

The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy
por: Homan, Claire C., et al.
Publicado: (2021)

The First Case of Acute Myeloid Leukemia With a Novel Five-way Variant Translocation of RUNX1–RUNX1T1
por: Jo, Yong Hun, et al.
Publicado: (2023)

The RUNX1/RUNX1T1 network: translating insights into therapeutic options
por: Swart, Laura E., et al.
Publicado: (2021)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
por: Garciaz, Sylvain, et al.
Publicado: (2022)

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
por: Zhang, Keyuan, et al.
Publicado: (2023)

The lncRNA RUNX1-IT1 regulates C-FOS transcription by interacting with RUNX1 in the process of pancreatic cancer proliferation, migration and invasion
por: Liu, Songsong, et al.
Publicado: (2020)

Acute myeloid leukemia with concurrent NPM1 and RUNX1 mutations
por: Zuo, Zhuang, et al.
Publicado: (2023)

Hemophagocytic Lymphohistiocytosis in RUNX1::RUNX1T1 Positive AML with Blast Count Below 20%
por: Huang, Xingqin, et al.
Publicado: (2023)

Complex rearrangement in acute myeloid leukemia M2 with RUNX1/RUNX1T1 fusion involving chromosomes 8, 17 and 21
por: Mishra, Shiba Ranjan, et al.
Publicado: (2021)

Thrombospondin-1 Is a Putative Target Gene of Runx2 and Runx3
por: Shi, Xiuming, et al.
Publicado: (2013)

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
por: Feld, Jonathan, et al.
Publicado: (2021)

RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia
por: Grinev, Vasily V., et al.
Publicado: (2021)

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2017)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

CD82 hypomethylation is essential for tuberculosis pathogenesis via regulation of RUNX1-Rab5/22
por: Koh, Hyun-Jung, et al.
Publicado: (2018)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

A Novel KIT INDEL Mutation in Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
por: Lee, Jun Hyung, et al.
Publicado: (2016)

RUNX1 and breast cancer
por: Mercado-Matos, Jose, et al.
Publicado: (2017)

RUNX1T1 function in cell fate
por: Hu, Nan, et al.
Publicado: (2022)

Unique N-terminal sequences in two Runx1 isoforms are dispensable for Runx1 function
por: Nieke, Sebastian, et al.
Publicado: (2017)

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
por: Bang, Su-Yeon, et al.
Publicado: (2023)

Images from the Haematologica Atlas of Hematologic Cytology: acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
por: Invernizzi, Rosangela
Publicado: (2022)

Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia
por: Grossmann, V, et al.
Publicado: (2012)

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2017)

Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
por: Ferrara, Felicetto
Publicado: (2020)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
por: Martini, Gianluca, et al.
Publicado: (2023)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8ju2eensai7ttnciqqjgcrl38b